Clinical Trial

METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin

Study acronym: METIMMOX-2
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Hypothesis: Patients with metastatic colorectal cancer with DNA mismatch repair-proficient (pMMR) function / microsatellite-stable (MSS) phenotype harbor a non-immunogenic disease that can be transformed into an immunogenic condition by short-course oxaliplatin-based therapy, and may achieve durable disease control or even tumor eradication by the addition of immune checkpoint blockade therapy to the standard-of-care oxaliplatin-based treatment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-08-15; most recent amendment 2026-01-06.
Status change: Recruiting → Active, Not Recruiting 2026-01-06
Status change: Not Yet Recruiting → Recruiting 2022-10-14
Trial Details
NCT Number NCT05504252
Lead Sponsor University Hospital, Akershus
Collaborators: Oslo University Hospital, St. Olavs Hospital
Conditions Colorectal Adenocarcinoma, Mucinous Adenocarcinoma, Signet Ring Cell Adenocarcinoma
Enrollment 80 participants
Start Date 2022-10-05
Primary Completion 2028-01-31 (estimated)
Study Completion 2028-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-07